Overview of Beta Thalassemia

Thalassaemia is the most common genetic disease in the world. It occurs when there are mutations/deletions in the alpha and/or beta globin genes. This results in reduced or absent synthesis of globin chains (for incorporation into Hb) and a hypochromic and microcytic blood picture. Start with beta thalassaemia because there are only two genes involved, so it's easier to understand and learn the difference between the heterozygous (beta thalassaemia trait/minor) and homozygous forms (beta thalassaemia major).Go through the pathophysiology, local and global distributions and tests (and expected results) used to investigate them.

Learning objectives for this topic are to be able to:

  1. Describe the inheritance pattern and underlying pathophysiology of:

    1. Beta thalassaemia silent

    2. Beta thalassaemia minor/trait

    3. Beta thalassaemia major

    4. Beta thalassaemia intermedia (this is a classification/category)

  2. List the tests (and expected results) used to investigate and confirm/diagnose them.

    1. FBC and blood film morphology

    2. Hb electrophoresis (HbEPP)

    3. High-performanvce liquid chromatography (HPLC)

    4. Molecular studies

  3. Describe the principle and rationale of the tests listed above (point 3).

  4. Describe the expected clinical features/presentation for the forms listed above (point 2).

Introduction to Beta Thalassemia

  • Beta thalassemia is classified as a microcytic disorder characterized by:

    • Hyperchromia

    • Reduced mean corpuscular hemoglobin (MCH)

Overview of Thalassemia

  • Two main types of thalassemia exist: alpha thalassemia and beta thalassemia.

  • Focus of the session is on beta thalassemia, which affects approximately 1.5% of the global population, making it the most common genetic abnormality worldwide.

    • Significance in haematology: Daily encounters with patients with milder forms of beta thalassemia in clinical settings.

Geographic Distribution

  • Common geographical regions for beta thalassemia:

    • Mediterranean regions

    • African countries

    • India

    • Southeast Asia

    • Indonesia

  • Global distribution is changing due to migration and interracial marriages, leading to increased cases in Northern Europe, America, and Australia.

Nomenclature and Notation

  • Notation used in thalassemia includes:

    • Beta globin gene symbolized as β

    • Genotypes and their representations:

    • Normal beta globin gene: $bb$

    • Beta null mutation (no production of beta globin): $β^0$

    • Beta plus mutation (reduced beta globin production): $β^+$

    • Mutations result in different phenotypic presentations:

    • Silent carriers: normal phenotype but carry a mutation.

Developmental Regulation of Hemoglobin Synthesis

  • Different hemoglobins are produced at various life stages:

    • Embryonic: Higher production of hemoglobin (e.g., Gower, Portland)

    • Fetal: Transition to hemoglobin F (two alpha and two gamma chains)

    • Adult: Transition to hemoglobin A (two alpha and two beta chains) around 6 months post-birth.

  • Genetic factors affecting hemoglobin production:

    • Beta thalassemia often caused by point mutations or frameshift mutations.

Types of Beta Thalassemia

  • Four primary classifications of beta thalassemia:

    • Beta Thalassemia Silent: No phenotypic expression occurs.

    • Beta Thalassemia Minor (Trait): Characterized by one abnormal beta globin gene (heterozygous).

    • Beta Thalassemia Major: Homozygous condition where both genes have mutations; presents with severe symptoms.

    • Beta Thalassemia Intermedia: Combination of beta thalassemia with other disorders; not strictly a diagnosis but a broad category.

Laboratory Investigation and Diagnosis

  • Tests performed for diagnosis:

    • Complete blood count:

    • Identify microcytic and hypochromic cells.

    • Private blood film analysis for red cell morphology.

    • Ferritin levels to rule out iron deficiency anemia.

    • Hemoglobin electrophoresis and high-performance liquid chromatography (HPLC) to quantify hemoglobin types.

Hemoglobin Characteristics

  • Normal adult hemoglobin composition:

    • Hemoglobin A: Majority (approximately 95%) is composed of two alpha and two beta chains.

    • Hemoglobin A2: Comprises two alpha and two delta chains (around 2-3%).

    • Hemoglobin F: Composed of two alpha and two gamma chains (less than 1-2%).

  • Thalassemia results in:

    • Defective or reduced synthesis of alpha or beta globin leading to reduced hemoglobin levels.

Pathophysiology of Beta Thalassemia

  • Autosomal recessive inheritance means:

    • Individuals can be heterozygous (carrier) or homozygous (affected).

  • Deficient beta globin synthesis increases ratios of unbalanced alpha globin chains: leads to ineffective erythropoiesis.

  • Clinical manifestations due to ineffective hemopoiesis lead to:

    • Extramedullary hemopoiesis (e.g., splenomegaly, hepatomegaly).

  • Increased erythroid precursors in bone marrow compensating for reduced hemoglobin synthesis.

Clinical Presentation and Consequences

  • Clinical features of beta thalassemia major:

    • Severe anemia with hypochromic microcytic red blood cells.

    • Characteristic peripheral blood film findings: polychromasia, target cells, and stains from basophilic stippling.

    • Complications from ineffective hemopoiesis such as splenomegaly affecting red blood cell removal.

    • Infants show developmental delays and failure to thrive due to inadequate oxygenation.

Beta Thalassemia Major

  • Characteristics:

    • Severe reduction or absence of beta globin chain synthesis leading to chronic hemolytic anemia.

    • Biochemical findings: Increased levels of hemoglobin F (>90%) and minor amounts of hemoglobin A2.

    • Treatment usually involves blood transfusions, leading to iron overload requiring chelation therapy.

Beta Thalassemia Minor (Trait)

  • Characteristics:

    • Typically asymptomatic with variable phenotypes.

    • Complete blood count shows microcytic, hypochromic red cells.

    • Normal to high red cell count with low MCV (around 60s or low 70s) and low MCH.

    • Increased hemoglobin A2 levels are key diagnostic indicators.

Clinical Outcomes and Genetics

  • Beta thalassemia intermedia denotes a range of phenotypes and does not refer to a single disorder.

  • Patients may or may not require transfusions and can present with varying degrees of anemia.

  • Genetic counseling and prenatal testing are essential for families with a history of thalassemia.

  • Conditions such as hemoglobin S and beta thalassemia have notable clinical implications and require specific management approaches.

Key Takeaways and Implications

  • Beta thalassemia is a complex genetic hemoglobinopathy requiring careful laboratory investigation for definitive diagnosis.

  • Understanding the genetic basis, pathophysiology, and clinical manifestations is crucial for management and treatment options.

  • The role of gene therapy and research on better treatment strategies continue to evolve, aiming to improve patient outcomes and quality of life for those affected.